Efficacy of lisdexamfetamine dimesylate throughout the day in children and adolescents with attention-deficit/hyperactivity disorder: results from a randomized, controlled trial

Lisdexamfetamine dimesylate (LDX) is a long-acting, prodrug stimulant therapy for patients with attention-deficit/hyperactivity disorder (ADHD). This randomized placebo-controlled trial of an optimized daily dose of LDX (30, 50 or 70 mg) was conducted in children and adolescents (aged 6–17 years) wi...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Coghill, David R., Banaschewski, Tobias, Lecendreux, Michel, Zuddas, Alessandro, Dittmann, Ralf W., Otero, Isabel Hernández, Civil, Richard, Bloomfield, Ralph, Squires, Liza A.
Format: Artigo
Langue:Inglês
Publié: Springer Berlin Heidelberg 2013
Sujets:
Original Contribution
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3918120/
https://ncbi.nlm.nih.gov/pubmed/23708466
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00787-013-0421-y
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires